JP2003531835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003531835A5 JP2003531835A5 JP2001575615A JP2001575615A JP2003531835A5 JP 2003531835 A5 JP2003531835 A5 JP 2003531835A5 JP 2001575615 A JP2001575615 A JP 2001575615A JP 2001575615 A JP2001575615 A JP 2001575615A JP 2003531835 A5 JP2003531835 A5 JP 2003531835A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- compound according
- linker
- group
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 21
- 125000000539 amino acid group Chemical group 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000013522 chelant Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- -1 Amino Chemical group 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical group OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Substances OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- UQTZMGFTRHFAAM-ZETCQYMHSA-N 3-iodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(I)=C1 UQTZMGFTRHFAAM-ZETCQYMHSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0009042.3 | 2000-04-12 | ||
| GB0009042A GB0009042D0 (en) | 2000-04-12 | 2000-04-12 | Contrast agents |
| GB0025070.4 | 2000-10-12 | ||
| GB0025070A GB0025070D0 (en) | 2000-10-12 | 2000-10-12 | Contrast agents |
| PCT/NO2001/000146 WO2001077145A2 (en) | 2000-04-12 | 2001-04-06 | Integrin binding peptide derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003531835A JP2003531835A (ja) | 2003-10-28 |
| JP2003531835A5 true JP2003531835A5 (https=) | 2011-08-04 |
| JP5043271B2 JP5043271B2 (ja) | 2012-10-10 |
Family
ID=26244091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001575615A Expired - Lifetime JP5043271B2 (ja) | 2000-04-12 | 2001-04-06 | ペプチドベースの化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7351790B2 (https=) |
| EP (1) | EP1272507B1 (https=) |
| JP (1) | JP5043271B2 (https=) |
| KR (2) | KR100879702B1 (https=) |
| CN (1) | CN1230441C (https=) |
| AT (1) | ATE298763T1 (https=) |
| AU (2) | AU2001250683B2 (https=) |
| CA (1) | CA2405469C (https=) |
| DE (1) | DE60111733T2 (https=) |
| DK (1) | DK1272507T3 (https=) |
| ES (1) | ES2244607T3 (https=) |
| HK (1) | HK1052711A1 (https=) |
| NO (1) | NO331741B1 (https=) |
| NZ (1) | NZ521735A (https=) |
| PT (1) | PT1272507E (https=) |
| WO (1) | WO2001077145A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7452551B1 (en) | 2000-10-30 | 2008-11-18 | Imarx Therapeutics, Inc. | Targeted compositions for diagnostic and therapeutic use |
| CA2405469C (en) * | 2000-04-12 | 2012-03-20 | Amersham Health As | Integrin binding peptide derivatives |
| NO20004795D0 (no) * | 2000-09-26 | 2000-09-26 | Nycomed Imaging As | Peptidbaserte forbindelser |
| BRPI0210886B8 (pt) * | 2001-07-10 | 2021-05-25 | Amersham Health As | composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal |
| US7452965B2 (en) | 2002-04-05 | 2008-11-18 | University Of Utah Research Foundation | Colon tumor specific binding peptides |
| CN100491395C (zh) * | 2002-04-11 | 2009-05-27 | 阿斯比奥制药株式会社 | 修饰肽的制造方法 |
| GB0224799D0 (en) * | 2002-10-25 | 2002-12-04 | Amersham Plc | Improved complex compositions |
| NO20030115D0 (no) * | 2003-01-09 | 2003-01-09 | Amersham Health As | Kontrastmiddel |
| NO20033115D0 (no) * | 2003-07-08 | 2003-07-08 | Amersham Health As | Peptid-baserte forbindelser |
| GB0317815D0 (en) | 2003-07-30 | 2003-09-03 | Amersham Health As | Imaging agents |
| ATE447417T1 (de) | 2004-03-04 | 2009-11-15 | Ge Healthcare As | Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie |
| RU2393167C2 (ru) * | 2004-06-16 | 2010-06-27 | Джи-И Хелткер АС | Пептидные соединения |
| JP5280682B2 (ja) * | 2004-06-16 | 2013-09-04 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | ペプチド系化合物 |
| EP1765172B1 (en) * | 2004-06-18 | 2013-04-24 | Elmaleh, David R. | Intravascular imaging device and uses thereof |
| DE602005025911D1 (de) | 2004-11-22 | 2011-02-24 | Ge Healthcare As | Kontrastmittel für eine extrazelluläre matrix |
| GB0428012D0 (en) * | 2004-12-22 | 2005-01-26 | Hammersmith Imanet Ltd | Radiolabelling methods |
| EP1833512A1 (en) * | 2005-01-06 | 2007-09-19 | GE Healthcare AS | Optical imaging |
| US8926945B2 (en) | 2005-10-07 | 2015-01-06 | Guerbet | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium |
| US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
| EP2056886A2 (en) * | 2006-08-28 | 2009-05-13 | GE Healthcare Limited | 68ga-labeled peptide-based radiopharmaceuticals |
| WO2008072973A2 (en) * | 2006-12-11 | 2008-06-19 | Ge Healthcare As | Radiolabelled peptide based compounds and uses thereof |
| US20090004119A1 (en) * | 2007-06-27 | 2009-01-01 | Ge Healthcare As | Polymers |
| DE102007036570A1 (de) | 2007-08-03 | 2009-02-19 | Siemens Ag | Screeningtest zur Erkennung von Prostataerkrankungen sowie Vorrichtung und Diagnosesubstanz zur Durchführung des Tests |
| US20100178245A1 (en) * | 2009-01-13 | 2010-07-15 | Arnsdorf Morton F | Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites |
| FR2942227B1 (fr) | 2009-02-13 | 2011-04-15 | Guerbet Sa | Utilisation de tampons pour la complexation de radionucleides |
| FR2968999B1 (fr) | 2010-12-20 | 2013-01-04 | Guerbet Sa | Nanoemulsion de chelate pour irm |
| FR2980364B1 (fr) | 2011-09-26 | 2018-08-31 | Guerbet | Nanoemulsions et leur utilisation comme agents de contraste |
| FR3001154B1 (fr) | 2013-01-23 | 2015-06-26 | Guerbet Sa | Magneto-emulsion vectorisee |
| KR20180100302A (ko) * | 2015-10-23 | 2018-09-10 | 우니베르지태트 트벤테 | 인테그린 결합 펩티드 및 그의 용도 |
| AU2018321825A1 (en) * | 2017-08-19 | 2020-03-05 | Ohio State Innovation Foundation | Novel peptide-based cancer imaging agents |
| WO2020007822A1 (en) | 2018-07-02 | 2020-01-09 | Conservatoire National Des Arts Et Metiers (Cnam) | Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof |
| JPWO2020230780A1 (https=) * | 2019-05-14 | 2020-11-19 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4647447A (en) * | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
| JP2833766B2 (ja) | 1987-07-16 | 1998-12-09 | ニユコメド・アクシエセルカペト | アミノポリカルボン酸およびその誘導体 |
| US5753627A (en) * | 1988-12-05 | 1998-05-19 | Novartis Ag | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis |
| US5364613A (en) * | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| IE901736L (en) | 1989-05-17 | 1990-11-17 | Fuller H B Licensing Financ | Polypeptide-antibody conjugate for inhibiting cell adhesion |
| US5367080A (en) * | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| UA43823C2 (uk) | 1992-07-06 | 2002-01-15 | Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН |
| US5981478A (en) * | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| DE69527194T2 (de) | 1994-03-28 | 2003-02-06 | Daiichi Pharmaceutical Co., Ltd. | Liposomen enthaltend ein röntgen- oder ultraschallkontrastmittel |
| US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| GB9420390D0 (en) | 1994-10-10 | 1994-11-23 | Nycomed Salutar Inc | Liposomal agents |
| ATE308981T1 (de) | 1995-08-14 | 2005-11-15 | Scripps Research Inst | Verfahren und mittel zur hemmung der durch alpha v beta 5 vermittelten angiogenese |
| JP3900305B2 (ja) | 1995-09-11 | 2007-04-04 | ザ バーナム インスティテュート | インビボにおいて選択された器官または組織に帰巣する分子および同分子を同定する方法 |
| CA2242647A1 (en) | 1996-01-10 | 1997-07-17 | Amersham Health As | Contrast media |
| AU709778B2 (en) | 1996-02-09 | 1999-09-09 | Steinel Gmbh & Co. Kg | Device for evaporating a liquid active substance |
| CA2265484C (en) | 1996-09-10 | 2008-12-02 | The Burnham Institute | Tumor homing molecules, conjugates derived therefrom, and methods of using same |
| GB9708265D0 (en) * | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
| CA2291323A1 (en) | 1997-05-28 | 1998-12-03 | Genvec, Inc. | Alternatively targeted adenovirus |
| GB9711115D0 (en) | 1997-05-29 | 1997-07-23 | Inst Of Child Health | Integrin-targeting vectors having enhanced transfection activity |
| IL137681A0 (en) | 1998-02-06 | 2001-10-31 | Uab Research Foundation | Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob |
| AU2662999A (en) | 1998-02-09 | 1999-08-23 | Genzyme Corporation | Nucleic acid delivery vehicles |
| CA2405469C (en) * | 2000-04-12 | 2012-03-20 | Amersham Health As | Integrin binding peptide derivatives |
| NO20033115D0 (no) * | 2003-07-08 | 2003-07-08 | Amersham Health As | Peptid-baserte forbindelser |
-
2001
- 2001-04-06 CA CA2405469A patent/CA2405469C/en not_active Expired - Fee Related
- 2001-04-06 CN CNB018109411A patent/CN1230441C/zh not_active Expired - Lifetime
- 2001-04-06 JP JP2001575615A patent/JP5043271B2/ja not_active Expired - Lifetime
- 2001-04-06 NZ NZ52173501A patent/NZ521735A/xx not_active IP Right Cessation
- 2001-04-06 AU AU2001250683A patent/AU2001250683B2/en not_active Ceased
- 2001-04-06 HK HK03104595.8A patent/HK1052711A1/zh unknown
- 2001-04-06 AU AU5068301A patent/AU5068301A/xx active Pending
- 2001-04-06 KR KR1020087007515A patent/KR100879702B1/ko not_active Expired - Fee Related
- 2001-04-06 ES ES01924011T patent/ES2244607T3/es not_active Expired - Lifetime
- 2001-04-06 PT PT01924011T patent/PT1272507E/pt unknown
- 2001-04-06 EP EP01924011A patent/EP1272507B1/en not_active Expired - Lifetime
- 2001-04-06 WO PCT/NO2001/000146 patent/WO2001077145A2/en not_active Ceased
- 2001-04-06 AT AT01924011T patent/ATE298763T1/de active
- 2001-04-06 DK DK01924011T patent/DK1272507T3/da active
- 2001-04-06 DE DE60111733T patent/DE60111733T2/de not_active Expired - Lifetime
- 2001-04-06 KR KR1020027013674A patent/KR100866666B1/ko not_active Expired - Fee Related
-
2002
- 2002-10-11 US US10/269,575 patent/US7351790B2/en not_active Expired - Lifetime
- 2002-10-14 NO NO20024932A patent/NO331741B1/no not_active IP Right Cessation
-
2008
- 2008-03-24 US US12/053,829 patent/US8404802B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003531835A5 (https=) | ||
| EP0429626B1 (en) | Synthetic peptides for use in vivo in thrombus detection | |
| Schibli et al. | Influence of the denticity of ligand systems on the in vitro and in vivo behavior of 99mTc (I)− tricarbonyl complexes: a hint for the future functionalization of biomolecules | |
| KR860001151B1 (ko) | 메탈로티오나인 및 표적탐색용 생물학적 활성 분자의 추적-표지된 접합체의 제조방법 | |
| KR940701275A (ko) | 영상화용 테크네튬-99m 표지화 펩티드 | |
| JPH07506086A (ja) | 撮像用テクネチウム−９９ｍ標識ペプチド | |
| JPH11503420A (ja) | 診断および治療用放射性標識ペプチド | |
| CA2405469A1 (en) | Integrin binding peptide derivatives | |
| JP3795521B2 (ja) | ペプチド−キレート化剤複合体 | |
| JPH08502075A (ja) | 標識された単球走化性因子タンパク質材料およびその医学的使用 | |
| JPH07504902A (ja) | 炎症造影用のテクネチウム−９９ｍ標識ペプチド | |
| CN1087630C (zh) | 血栓成像用的放射性标记化合物 | |
| CN102316903A (zh) | Pdgf-rbeta结合剂 | |
| EP2271373A2 (en) | 99mtc-labeled 19 amino acid containing peptide for use as phosphatidylethanolamine binding molecular probe and radiopharmaceutical | |
| KR100385340B1 (ko) | 금속킬레이트형성펩티드및그의용도 | |
| KR940018398A (ko) | 혈관 질병 진단제 | |
| JP2008504237A5 (https=) | ||
| JP2008520658A5 (https=) | ||
| RU2007118385A (ru) | Контрастные агенты для направлений доставки во внеклеточный матрикс | |
| JP2004524323A5 (https=) | ||
| DE69526203T2 (de) | Biologische zielgerichtete mittel | |
| MXPA05004418A (es) | Conjugados de complejos de tc y porciones enfocadoras y su uso en diagnostico de mri. | |
| WO2023100852A1 (ja) | 安定化放射性医薬組成物 | |
| JP2564459B2 (ja) | 放射性医薬品調製用キャリヤー | |
| CN116456992A (zh) | 抗her2抗体的放射性复合物和放射性药物 |